On the 27th of October 2020, Amniotics was approved to carry out activities as a Tissue Establishment by the Swedish Medical Products Agency. The authorization refers to the handling of human tissues and cells intended for the manufacture of medicinal products (ATMPs).
Amniotics COO Jan Talts will be Head of Operations and Andreas Herbst, CMO, board member and one of the founders of Amniotics, will take the role as Specially Appointed Responsible Physician.
Dr. Herbst is Chief Physician and specialist in obstetrics and was previously Head of Operations for Obstetrics and Gynecology at Skåne University Hospital and Chairman of the Swedish Society for Obstetrics and Gynecology.
“It is very pleasing that Andreas has decided to extend his commitment to Amniotics and that we now can engage Andreas a little closer in Amniotics clinical work”, says Amniotics CEO Kåre Engkilde.
“I am very happy to have the chance to be more engaged with Amniotics and I relish the chance to bring Amniotics cell therapies closer towards clinical use”, says Andreas Herbst.